The use of conjugates such as GLP-1/T 3 could serve as a Trojan horse delivery system where internalisation through a functional GLP-1 receptor might deliver T 3 to the brain, ameliorating the disease (and potentially other similar human genetic deficiencies)
GLP-1s AdventHealth Choose the health content thats right for you, and get it delivered right in your inbox
CANVAS demonstrated a 14% reduction in MACE in patients with T2DM and a high cardiovascular risk ( 4.1.2 Cardiovascular results in studies aimed at CVD The CREDENCE clinical trial evaluated the effects of canagliflozin (100 mg daily) versus placebo in 4,401 patients with T2DM and CKD
This is a problem we call the Quality-Price Gap. We put Hers under the microscope to see how it measures up on safety, cost, and long-term support, helping you bridge the gap between safety and affordability
9. Stout JR et al. Exp Gerontol. 2015;64:33-34. 10. Deutz et al. Clin Nutr. 2013;32(5):704-712
To generate novel information about the functional pathways represented by these potential GLP-1R interactors, we performed pathway enrichment analysis with the GLP-1R binding partners exhibiting changes between vehicle and exendin-4-stimulated conditions using gProfiler
